Trial reportAddiction biology2017
Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
Trial report in Addiction biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Relief craving severity moderates nonpharmacological treatment outcomes in treatment-seeking older adults with alcohol use disorder.Alcohol, clinical & experimental research · 2025Trial
- Characterizing reward and relief/habit drinking profiles in a study of naltrexone, varenicline, and placebo.Alcohol and alcoholism (Oxford, Oxfordshire) · 2024Trial
- Reward, relief, and habit drinking profiles in treatment seeking individuals with an AUD.Alcohol and alcoholism (Oxford, Oxfordshire) · 2024Trial
- An intensive longitudinal examination of topiramate treatment for alcohol use disorder: a secondary analysis of data from a randomized controlled trial.Addiction (Abingdon, England) · 2023Trial
- Reward drinking and naltrexone treatment response among young adult heavy drinkers.Addiction (Abingdon, England) · 2021Trial
- Applying methods for personalized medicine to the treatment of alcohol use disorder.Journal of consulting and clinical psychology · 2021Trial
- A Multimethod Examination of Sensitivity to Reward and Sensitivity to Punishment in Bipolar Disorder and Alcohol Dependence: Results from a 2 × 2 Factorial Design.Psychopathology · 2021Trial
- Advancing Precision Medicine for Alcohol Use Disorder: Replication and Extension of Reward Drinking as a Predictor of Naltrexone Response.Alcoholism, clinical and experimental research · 2019Trial
- Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Trial
- Craving mediates the association between affect and substance use in daily life among individuals with substance use disorders.Drug and alcohol dependence reports · 2026Article
- Randomized trial of a single-session digital intervention targeting emotion-related beliefs and emotion regulation.Scientific reports · 2026Article
- Case report: Acamprosate for treatment of volatile hydrocarbon (VHC) inhalant use disorder with comorbid alcohol use disorder.The mental health clinician · 2026Article
- Nalmefene and naltrexone reduce alcohol intake via selective efficacy in subpopulations distinguished by behavioral and blood-based biomarkers.Communications medicine · 2026Article
- Ecological momentary assessment and mediation analyses reveal relationships between affect, craving, and substance use in daily life.medRxiv : the preprint server for health sciences · 2025Article
- Finding purpose: Integrated latent profile and machine learning analyses identify purpose in life as an important predictor of high-functioning recovery after alcohol treatment.Addictive behaviors · 2025Article
- Next-generation biomarkers for alcohol consumption and alcohol use disorder diagnosis, prognosis, and treatment: A critical review.Alcohol, clinical & experimental research · 2025Review
- Comparing the psychometric properties of reward and relief drinking measures.Experimental and clinical psychopharmacology · 2024Article
- Drinking motives link positive and negative life events to problematic alcohol use during the COVID-19 pandemic: a longitudinal study.Alcohol and alcoholism (Oxford, Oxfordshire) · 2024Article
- Kappa-opioid receptor stimulation in the nucleus accumbens shell and ethanol drinking: Differential effects by rostro-caudal location and level of drinking.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Longitudinal stability of reward and relief drinking phenotypes in community and treatment-seeking individuals who engage in heavy drinking.Alcohol, clinical & experimental research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Researchers have sought to distinguish between individuals whose alcohol use disorder (AUD) is maintained by drinking to relieve negative affect ('relief drinkers') and those whose AUD is maintained by the rewarding effects of alcohol ('reward drinkers'). As an opioid receptor antagonist, naltrexone may be particularly effective for reward drinkers. Acamprosate, which has been shown to down-regulate the glutamatergic system, may be particularly effective for relief drinkers. This study sought to replicate and extend prior work (PREDICT study; Glöckner-Rist et al. ) by examining dimensions of reward and relief temptation to drink and subtypes of individuals with distinct patterns of reward/relief temptation. We utilized data from two randomized clinical trials for AUD (Project MATCH, n = 1726 and COMBINE study, n = 1383). We also tested whether classes of reward/relief temptation would predict differential response to naltrexone and acamprosate in COMBINE. Results replicated prior work by identifying reward and relief temptation factors, which had excellent reliability and construct validity. Using factor mixture modeling, we identified five distinct classes of reward/relief temptation that replicated across studies. In COMBINE, we found a significant class-by-acamprosate interaction effect. Among those most likely classified in the high relief/moderate reward temptation class, individuals had better drinking outcomes if assigned to acamprosate versus placebo. We did not find a significant class-by-naltrexone interaction effect. Our study questions the orthogonal classification of drinkers into only two types (reward or relief drinkers) and adds to the body of research on moderators of acamprosate, which may inform clinical decision making in the treatment of AUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.